TRYNGOLZA™ (olezarsen) approved in U.S. as first-ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to diet December 20, 2024 by True Academy Comments are off Posted in:Stock Market & Investment NewsTagged with:Buy Sell ShareFTSEKLCIMalaysiaPelaburanSahamShare Trading See more Prev:FCPT Announces Sale Leaseback of Two Riverview Health Outpatient Primary Care Properties for $13.5 Million Back: All Posts Next:Zscaler CFO Remo Canessa sells $1.38 million in stock